Ara Kocharyan

The mission of F·E·G·S Health and Human Services System has remained constant for almost three-quarters of a century: To meet the needs of the Jewish and broader community through a diverse network of high quality, cost-efficient health and human services that help each person achieve greater independence at work, at home, at school and in the community, and meet the ever-changing needs of business and society. F·E·G·S has assisted more than three million people since its founding in 1934 by the Federation of Jewish Philanthropies, now UJA-Federation of New York, of which F·E·G·S is a beneficiary agency. Today, F·E·G·S is one of the largest and most diversified not-for-profit health and human services organizations in the United States.

Emvolio, Inc. develops cancer drugs.

Sandbox Dental Labs, Inc. operates a dental laboratory.

OmniBiome, Inc. manufactures diagnostic kits. It focuses on developing Dx/Rx products and services for pre-pregnancy-associated and pregnancy-associated conditions or diseases where there is a substantive putative link with microbiome dysbiosis, as well as on restoring eubiosis. The company is headquartered in Oceanside, CA.

MolecuVax, Inc. manufactures biopharmaceutical products. It offers MVAX-001, a cancer stem cell targeted immunotherapy that activates the immune system to seek and destroy cancer stem cells based on their expression of a protein named Brother of the Regulator of Imprinted Sites (BORIS). The company is headquartered in Oceanside, CA.

Canary Oncoceutics, Inc. develops a precision oncology testing platform. The CEO of the American company is Harry M. Lander.

Zander Therapeutics, Inc. engages in the development and commercialization of veterinary medical therapies. It focuses on developing small molecule immunotherapies and cancer stem cell therapies for the veterinary market. The company was founded on July 18, 2015 and is headquartered in La Mesa, CA.

Sidra Medical & Research Center is a state-of-the-art tertiary hospital located in Doha, Qatar that serves women and children. The hospital provides world-class healthcare services and is also a renowned science and research center committed to developing innovative approaches to medical care.

Vaxine Pty Ltd. is an Australian biotechnology company that specializes in researching and developing vaccines and drugs against pathogens that pose major public health or biodefense threats. The company is based in Adelaide, Australia, and is a leading producer of vaccines and immunotherapies, including vaccines against COVID-19, influenza, hepatitis B, and Japanese encephalitis, plus immunotherapies against allergy and cancer. Vaxine has received extensive funding support from the government for its pandemic vaccine development programs and has worked extensively with US Army researchers to develop vaccines against a range of exotic pathogens. At the center of Vaxine's technological prowess lies Advax™, one of the first major breakthroughs in vaccine adjuvants in almost a hundred years. The company was founded in 2002 by Professor Nikolai Petrovsky, a world-leading vaccine expert based at Flinders University in Adelaide, South Australia.